Let's check out two exciting biotech stocks that may climb 58% and 200%, according to Wall Street. Image source: Getty Images ...

It's thanks to these efforts that Exelixis' financial results have been solid. Revenue, earnings, and free cash flow have all ...

Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

2026 could be a big year for this company.

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo Stock Exchange next week, the business’ CEO has confirmed. | Japan-based cell therapy company ...

Multibagger stock: Titan Biotech shares surged 20% to ₹312 after a 1:5 stock split, enhancing liquidity and making shares ...